0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL3

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Role of RNA modifications in cancer

          Specific chemical modifications of biological molecules are an efficient way of regulating molecular function, and a plethora of downstream signalling pathways are influenced by the modification of DNA and proteins. Many of the enzymes responsible for regulating protein and DNA modifications are targets of current cancer therapies. RNA epitranscriptomics, the study of RNA modifications, is the new frontier of this arena. Despite being known since the 1970s, eukaryotic RNA modifications were mostly identified on transfer RNA and ribosomal RNA until the last decade, when they have been identified and characterized on mRNA and various non-coding RNAs. Increasing evidence suggests that RNA modification pathways are also misregulated in human cancers and may be ideal targets of cancer therapy. In this Review we highlight the RNA epitranscriptomic pathways implicated in cancer, describing their biological functions and their connections to the disease.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              m6A RNA methylation regulates the UV-induced DNA damage response

              Cell proliferation and survival require the faithful maintenance and propagation of genetic information, which are threatened by the ubiquitous sources of DNA damage present intracellularly and in the external environment. A system of DNA repair, called the DNA damage response (DDR), detects and repairs damaged DNA and prevents cell division until the repair is complete. Here we report that methylation at the 6 position of adenosine (m6A) in RNA is rapidly (within 2 minutes) and transiently induced at DNA damage sites in response to UV. This modification occurs on numerous poly(A)+ transcripts and is regulated by the methyltransferase METTL3 1 and the demethylase FTO 2 . In the absence of METTL3 catalytic activity, cells showed delayed repair of UV-induced cyclobutane pyrimidine (CPD) adducts and elevated sensitivity to UV, demonstrating the importance of m6A in the UV-responsive DDR. Multiple DNA polymerases are involved in the UV response, some of which resynthesize DNA after the lesion has been excised by the nucleotide excision repair (NER) pathway 3 , while others participate in trans-lesion synthesis (TLS) to allow replication past damaged lesions in S phase 4 . DNA polymerase κ (Pol κ), which has been implicated in both NER and TLS 5,6 , required the catalytic activity of METTL3 for immediate localization to UV-induced DNA damage sites. Importantly, Pol κ over-expression qualitatively suppressed the CPD removal defect associated with METTL3 loss. Taken together, we have uncovered a novel function for RNA m6A modification in the UV-induced DDR, and our findings collectively support a model whereby m6A RNA serves as a beacon for the selective, rapid recruitment of Pol κ to damage sites to facilitate repair and cell survival.
                Bookmark

                Author and article information

                Contributors
                francesco.fazi@uniorma1.it
                alessandro.fatica@uniroma1.it
                Journal
                Cancer Commun (Lond)
                Cancer Commun (Lond)
                10.1002/(ISSN)2523-3548
                CAC2
                Cancer Communications
                John Wiley and Sons Inc. (Hoboken )
                2523-3548
                15 December 2023
                February 2024
                : 44
                : 2 ( doiID: 10.1002/cac2.v44.2 )
                : 282-286
                Affiliations
                [ 1 ] Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology Sapienza University of Rome Rome Italy
                [ 2 ] Department of Biology and Biotechnologies “Charles Darwin” Sapienza University of Rome Rome Italy
                [ 3 ] GSTeP Organoids Research Core Facility Fondazione Policlinico A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Rome Italy
                [ 4 ] Department of Drug Chemistry and Technologies Sapienza University of Rome Rome Italy
                [ 5 ] Pasteur Institute, Cenci‐Bolognetti Foundation, Sapienza University of Rome Rome Italy
                [ 6 ] Department of BioSciences University of Milan Milan Italy
                [ 7 ] Multidisciplinary Breast Center, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Catholic University of the Sacred Heart Rome Italy
                [ 8 ] Department of Neuroscience, Section of Human Anatomy Catholic University of the Sacred Heart Rome Italy
                [ 9 ] Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute Rome Italy
                Author notes
                [*] [* ] Correspondence

                Alessandro Fatica, Department of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, P.le Aldo Moro 5, Rome 00185, Italy.

                Email: alessandro.fatica@ 123456uniroma1.it

                Francesco Fazi, Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Via Scarpa 16, Rome 00161, Italy.

                Email: francesco.fazi@ 123456uniorma1.it

                Author information
                https://orcid.org/0000-0001-8332-8842
                https://orcid.org/0000-0002-0743-7905
                Article
                CAC212509
                10.1002/cac2.12509
                10876187
                38102821
                c7c089ba-9dac-4fc0-9595-f2c3128f89bb
                © 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 28 November 2023
                : 04 August 2023
                : 03 December 2023
                Page count
                Figures: 1, Tables: 0, Pages: 5, Words: 2710
                Funding
                Funded by: NextGenerationEU‐PNRR M4C2‐Investment 1.4
                Award ID: CN00000041
                Funded by: Progetti Ateneo Sapienza
                Award ID: RP1201729D714976
                Funded by: Breast Cancer now
                Award ID: 2018NovPCC1283
                Funded by: Associazione Italiana per la Ricerca sul Cancro , doi 10.13039/501100005010;
                Award ID: IG23416
                Categories
                Letter to the Editor
                Letters to the Editor
                Custom metadata
                2.0
                February 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.8 mode:remove_FC converted:19.02.2024

                Comments

                Comment on this article